Is MGRM's EPS stagnation a concern for investors?

**Monogram Technologies Inc. (MGRM) faces challenges in terms of EPS stagnation and net loss**, which could be a concern for investors. Here's an analysis based on the latest data and market sentiment: 1. **EPS Stagnation and Net Loss**: Monogram reported a GAAP EPS of -$0.46 for the year ended December 31, 2024, which beats the consensus estimate by $0.03. However, this does not necessarily indicate a positive trend as the EPS is negative, and the company has a history of net losses, with a net loss of $16.3 million for 2024 compared to $13.7 million for 2023. |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |MGRM|MGRM.O|Monogram|2024 Q1|72.50000000000001|-0.11|186| |MGRM|MGRM.O|Monogram|2024 Q2|59.25925925925927|-0.11|186| |MGRM|MGRM.O|Monogram|2024 Q3|-433.33333333333337|-0.16|186| 2. **Analyst Sentiment and Price Target**: Despite the challenges, analysts have a positive outlook on Monogram, with a consensus rating of "Strong Buy" and an average price target of $5.4, indicating potential confidence in the company's future performance. 3. **Earnings Estimates and Market Performance**: Zacks Small Cap analyst T. Kerr expects Q1 2025 EPS to be ($0.10), with a full-year estimate of ($0.49) per share. This suggests that the company is expected to continue facing challenges in the near term. Monogram's stock has seen a 57.5% trading increase, with a market cap of $129.51 million, a PE ratio of -7.81, and a beta of 1.66. 4. **Commercialization Potential and Regulatory Updates**: The potential commercialization of Monogram's mBôs Total Knee Arthroplasty Robotic System supports a price target of $6.00. Additionally, the company's regulatory updates and formal response to FDA requests indicate ongoing efforts to navigate the regulatory landscape. In conclusion, while Monogram's EPS stagnation and net losses are concerning, the positive analyst sentiment, potential for commercialization, and regulatory progress suggest that investors should monitor the company's trajectory closely but maintain a cautious optimism. The average price target of $5.4 indicates a potential upside from the current price, which could be a consideration for investors looking for growth opportunities despite the risks.